Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $1.5 million for Q3 2022.

• Quarterly Current Deferred Revenue rose 16777.62% year-over-year to $1.5 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.5 million (up 16777.62% YoY) and the FY2022 annual result came in at $1.5 million, up 16777.62% from the prior year.
• Current Deferred Revenue grew to $1.5 million in Q3 2022, from $2248.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.5 million in Q3 2022 and bottomed at $2248.0 in Q4 2021.
• The 3-year median for Current Deferred Revenue is $13596.0 (2021), against an average of $182199.0.
• Year-over-year, Current Deferred Revenue sank 95.61% in 2021 and soared 16777.62% in 2022.
• Neuroone Medical Technologies' Current Deferred Revenue stood at $51160.0 in 2020, then sank by 95.61% to $2248.0 in 2021, then jumped by 64632.56% to $1.5 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.5 million, $2248.0, and $2248.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.